Dyslipidemia

Health benefits of gastric bypass surgery after 6 years

Top

Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308(11):1122-1131. This prospective study by Adams and colleagues explored the weight loss and cardiometabolic benefits of Roux-en-Y gastric bypass (RYGB) among severely obese patients over 6 years of follow-up.

Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults

Top

Neeland IJ, Turer AT, Ayers CR, Powell Wiley TM, Vega GL, Farzaneh Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150-1159. The risk of type 2 diabetes mellitus is heterogeneous among obese individuals. Factors that discriminate prediabetes or diabetes risk within this population have not been well characterized.

Statins and new-onset diabetes: a retrospective longitudinal cohort study

Top

Ma T, Tien L, Fang CL, Liou YS, Jong GP. Statins and new onset diabetes a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977-1983. Statins have been linked to new-onset diabetes (NOD); however, the effect of statins on the development of NOD in patients with hypertension and dyslipidemia has not been well studied.

Impaired fasting glucose and risk of cardiovascular disease in Korean men and women: The Korean Heart Study.

Top

Kim HK, Kim CH, Kim EH, Bae SJ, Choe J, Park JY, Park SW, Yun YD, Baek SJ, Mok Y, Jee SH. Impaired fasting glucose and risk of cardiovascular disease in Korean men and women The Korean Heart Study. Diabetes Care. 2012 Sep 21. Epub ahead of print. The relationship between impaired fasting glucose (IFG) and risk of cardiovascular disease (CVD) or ischemic heart disease (IHD) varies widely according to sex and ethnicity. We evaluated the relationship between IFG and CVD or IHD among Korean men and women.

Waist-to-Height Ratio and Cardiovascular Risk Factors in Elderly Individuals at High Cardiovascular Risk

Top

Guasch-Ferré M, Bulló M, Martínez-González MÁ, Corella D, Estruch R, Covas MI, Arós F, Wärnberg J, Fiol M, Lapetra J, Muñoz MÁ, Serra-Majem L, Pintó X, Babio N, Díaz-López A, Salas-Salvadó J. Waist-to-Height Ratio and Cardiovascular Risk Factors in Elderly Individuals at High Cardiovascular Risk. PLoS One. 2012;7(8):e43275. Several anthropometric measurements have been associated with cardiovascular disease, type-2 diabetes mellitus and other cardiovascular risk conditions, such as hypertension or metabolic syndrome.

Predictors of mortality over 8 years in type 2 diabetic patients: Translating Research Into Action for Diabetes (TRIAD)

Top

McEwen LN, Karter AJ, Waitzfelder BE, Crosson JC, Marrero DG, Mangione CM, Herman WH. Diabetes Care. Predictors of mortality over 8 years in type 2 diabetic patients Translating Research Into Action for Diabetes (TRIAD). 2012 Mar 19. Epub ahead of print. To examine demographic, socioeconomic, and biological risk factors for all-cause, cardiovascular, and noncardiovascular mortality in patients with type 2 diabetes over 8 years and to construct mortality prediction equations.

Genetic predisposition to dyslipidemia and type 2 diabetes risk in two prospective cohorts

Top

Qi Q, Liang L, Doria A, Hu FB, Qi L. Genetic predisposition to dyslipidemia and type 2 diabetes risk in two prospective cohorts. Diabetes. 2012 Feb 7. Epub ahead of print. Dyslipidemia has been associated with type 2 diabetes, but it remains unclear whether dyslipidemia plays a causal role in type 2 diabetes.

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy

Top

Dicembrini I, Pala L, Rotella CM. From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy. Exp Diabetes Res. 2011;2011:898913. Epub 2011 Jun 23. Promoting long-term adherence to lifestyle modification and choice of antidiabetic agent with low hypoglycemia risk profile and positive weight profile could be the most effective strategy in achieving sustained glycemic control and in reducing comorbidities.

The pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention

Top

Pruski M, Krysiak R, Okopien B. The pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care. 2009 May 12. [Epub ahead of print]. To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia.

Pleiotropic action of short-term metformin & fenofibrate treatment, combined w lifestyle intervention, in type 2 diabetic patients w mixed dyslipidemia

Top

Pruski M, Krysiak R, Okopien B. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care. 2009;32(8):1421-1424. To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors, and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia.

1 2 3 4 5 Next